Literature DB >> 31165861

Nontuberculous Mycobacteria and Heterologous Immunity to Tuberculosis.

Javeed A Shah1,2, Cecilia S Lindestam Arlehamn3, David J Horne1, Alessandro Sette3,4, Thomas R Hawn1.   

Abstract

Development of an improved tuberculosis (TB) vaccine is a high worldwide public health priority. Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, provides variable efficacy against adult pulmonary TB, but why this protection varies is unclear. Humans are regularly exposed to non-tuberculous mycobacteria (NTM) that live in soil and water reservoirs and vary in different geographic regions around the world. Immunologic cross-reactivity may explain disparate outcomes of BCG vaccination and susceptibility to TB disease. Evidence supporting this hypothesis is increasing but challenging to obtain due to a lack of reliable research tools. In this review, we describe the progress and bottlenecks in research on NTM epidemiology, immunology and heterologous immunity to Mtb. With ongoing efforts to develop new vaccines for TB, understanding the effect of NTM on vaccine efficacy may be a critical determinant of success.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  BCG; adaptive immunity; innate immunity; nontuberculous mycobacteria; tuberculosis; vaccines

Mesh：

Substances：

Year:  2019        PMID： 31165861      PMCID： PMC6736075          DOI： 10.1093/infdis/jiz285

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  55 in total

1.  Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi.

Authors:  G F Black; H M Dockrell; A C Crampin; S Floyd; R E Weir; L Bliss; L Sichali; L Mwaungulu; H Kanyongoloka; B Ngwira; D K Warndorff; P E Fine
Journal:  J Infect Dis       Date:  2001-07-10       Impact factor: 5.226

2.  Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India.

Authors:  P R Narayanan
Journal:  Indian J Med Res       Date:  2006-02       Impact factor: 2.375

3.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination.

Authors:  David K Flaherty; Bridget Vesosky; Gillian L Beamer; Paul Stromberg; Joanne Turner
Journal:  J Leukoc Biol       Date:  2006-09-12       Impact factor: 4.962

5.  The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.

Authors:  G W de Lisle; B J Wards; B M Buddle; D M Collins
Journal:  Tuberculosis (Edinb)       Date:  2004-12-28       Impact factor: 3.131

6.  The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi.

Authors:  R E Weir; G F Black; B Nazareth; S Floyd; S Stenson; C Stanley; K Branson; L Sichali; S D Chaguluka; L Donovan; A C Crampin; P E M Fine; H M Dockrell
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

7.  Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States.

Authors:  C F von Reyn; C R Horsburgh; K N Olivier; P F Barnes; R Waddell; C Warren; S Tvaroha; A S Jaeger; A D Lein; L N Alexander; D J Weber; A N Tosteson
Journal:  Int J Tuberc Lung Dis       Date:  2001-12       Impact factor: 2.373

8.  BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.

Authors:  Gillian F Black; Rosemary E Weir; Sian Floyd; Lyn Bliss; David K Warndorff; Amelia C Crampin; Bagrey Ngwira; Lifted Sichali; Bernadette Nazareth; Jenefer M Blackwell; Keith Branson; Steven D Chaguluka; Linda Donovan; Elizabeth Jarman; Elizabeth King; Paul E M Fine; Hazel M Dockrell
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

9.  Nontuberculous mycobacterial sensitization in the United States: national trends over three decades.

Authors:  Kamran Khan; Jun Wang; Theodore K Marras
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

10.  Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans.

Authors:  Valerie J Quesniaux; Delphine M Nicolle; David Torres; Laurent Kremer; Yann Guérardel; Jérôme Nigou; Germain Puzo; François Erard; Bernhard Ryffel
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422
View more
  8 in total

Review 1.  Epitope prediction and identification- adaptive T cell responses in humans.

Authors:  John Sidney; Bjoern Peters; Alessandro Sette
Journal:  Semin Immunol       Date:  2020-10-31       Impact factor: 11.130

Review 2.  The knowns and unknowns of latent Mycobacterium tuberculosis infection.

Authors:  W Henry Boom; Ulrich E Schaible; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

3.  Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination.

Authors:  Michel P M Vierboom; Karin Dijkman; Claudia C Sombroek; Sam O Hofman; Charelle Boot; Richard A W Vervenne; Krista G Haanstra; Maarten van der Sande; Liesbeth van Emst; Jorge Domínguez-Andrés; Simone J C F M Moorlag; Clemens H M Kocken; Jelle Thole; Esteban Rodríguez; Eugenia Puentes; Joost H A Martens; Reinout van Crevel; Mihai G Netea; Nacho Aguilo; Carlos Martin; Frank A W Verreck
Journal:  Cell Rep Med       Date:  2021-01-19

Review 4.  Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.

Authors:  Stephen M Carpenter; Lenette L Lu
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

Review 5.  Nontuberculous Mycobacteria as Sapronoses: A Review.

Authors:  Ivo Pavlik; Vit Ulmann; Dana Hubelova; Ross Tim Weston
Journal:  Microorganisms       Date:  2022-07-03

6.  T-cell deficiency and hyperinflammatory monocyte responses associate with Mycobacterium avium complex lung disease.

Authors:  Cecilia S Lindestam Arlehamn; Basilin Benson; Rebecca Kuan; Kimberly A Dill-McFarland; Glenna J Peterson; Sinu Paul; Felicia K Nguyen; Robert H Gilman; Mayuko Saito; Randy Taplitz; Matthew Arentz; Christopher H Goss; Moira L Aitken; David J Horne; Javeed A Shah; Alessandro Sette; Thomas R Hawn
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

Review 7.  Is mapping the BCG vaccine-induced immune responses the key to improving the efficacy against tuberculosis?

Authors:  R Kuan; K Muskat; B Peters; C S Lindestam Arlehamn
Journal:  J Intern Med       Date:  2020-11-19       Impact factor: 13.068

Review 8.  Clinical Development of New TB Vaccines: Recent Advances and Next Steps.

Authors:  Mark Hatherill; Richard G White; Thomas R Hawn
Journal:  Front Microbiol       Date:  2020-01-30       Impact factor: 5.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.